Table 3. Distribution of Results by Assay, Specimen Type, HPV Type, and Collection Time.

SPECIMEN TYPE	HPV TYPE	SPECIMEN COLLECTION (Months)	N	GMT	SEAP-NA IQR	Spearman; p-value ^b	N	GMT	ELISA IQR	Spearman; p-value ^b

SERUM	HPV-16	0 1 12	5 50 50	34.3 373.5 4694.0	[5.7, 87.5] [100.8, 1151.2] [2366.3, 10107.0]	0.25; p=0.08 (0.54; p=0.0009)^a	5 50 50	9.6 510.2 2023.3	[4.0, 11.7] [229.7, 1240.0] [1068.7, 3403.5]	0.16; p=0.265 (0.47; p= 0.005)^a
	HPV-18	0 1 12	5 50 50	10.6 182.6 1926.9	[5.0, 27.3] [52.3, 397.6] [661.1, 4347.5]	0.37; p=0.009 (0.54; p=0.0009)^a	5 50 50	6.0 335.7 1149.1	[3.5, 12.0] [156.2, 865.5] [604.0, 2072.2]	0.38; p=0.007 (0.58; p=0.0004)^a

CERVICAL SECRETIONS^c	HPV-16	0 12	5 42	ND 326.6	ND [147.2, 679.8]		5 42	ND 130.0	ND [66.1, 354.2]
	HPV-18	0 12	5 42	ND 149.8	ND [62.7, 246.9]		5 42	ND 85.0	ND [40.2, 229.4]

GMT- Geometric Mean Titer

IQR- Interquartile range

Participants were excluded from the analyses due to receiving less than three doses of the HPV L1 VLP 16 and 18 vaccine (n=4) as well as having month 1 antibody titers greater than month12 (n=14) for a single assay.

Spearman rank correlation coefficients are based on month 1 vs. month 12 for serum samples only.

Cervical secretions are adjusted for sponge weight.